BioFocus

Type: Company
Name: BioFocus
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

KISS supports Health Enterprise East Innovation Competition with gold sponsorship

KISS Communications is delighted to sponsor the Health Innovation Competition, organised by Health Enterprise East (HEE), a leading NHS Innovation Hub.The competition celebrates the best ideas from colleagues of all grades and levels across the NHS, culminating ... [Published Cambridge Network - Sep 02 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

KISS Continues to Ramp Up Investment in Young Talent

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.SOURCE:Integrated creative agency KISS Communications continues to invest in young people with its thriving ... [Published WKRG - Aug 29 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 1 reports

Charles River reports higher Q2 net income, updates guidance for 2014

Charles River Laboratories International, Inc., a provider of preclinical and clinical laboratory services, has reported that net income attributable to common shareowners for the second quarter ended June 28, 2014 was $35.26 million, or $0.74 per diluted ... [Published Individual.com - Aug 21 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Galapagos cash position of €232 M provides solid basis for R&D pipeline investment

Net profit of €56 M for first half 2014• Solid cash balance of €232 M on 30 June 2014, liquid assets position of €240 M• Group revenues €63 M, including €18 M revenues from discontinued service operations• Operating loss of continuing operations €15 M, ... [Published Noodls - Aug 18 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

CHARLES RIVER LABORATORIES : Announces Second-Quarter 2014 Results from Continuing Operations

By a News Reporter-Staff News Editor at Investment Weekly News -- Charles River Laboratories International, Inc. (NYSE: CRL) reported its results for the second quarter of 2014. For the quarter, revenue from continuing operations was $341.2 million , ... [Published 4 Traders - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

KISS team cycles from London to Cambridge, raising over £900 for Breakthrough Breast Cancer

On Sunday 27th July, a 12-strong team from KISS Communications, a leading Cambridge creative agency, undertook the gruelling 60 mile London to Cambridge cycle challenge in a bid to raise money for Breakthrough Breast Cancer, a worthy charity dedicated ... [Published Cambridge Network - Aug 14 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

CRL to buy Argenta and Biofocus from Galapagos for €134m

Preclinical CRO Charles River Labs has announced plans to buy discovery services firms Argenta and BioFocus from Galapagos NV.The deal values the two firms at €134m ($187m), €129m of which will be paid upfront with a further €5m later based on the achievement ... [Published Outsourcing Pharma - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Charles River's checkbook fuels a leap in revenue

Charles River Laboratories ($CRL) is dialing up its expectations for the year after some M&A padded its second-quarter results, riding a 16.5% boost in sales.The CRO's revenue came in at $341.2 million, with its recent $179 million acquisition of Galapagos' ... [Published Fierce CRO - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Galapagos cash position of EU232 M provides solid basis for R&D pipeline investment

Net profit of €56 M for first half 2014Solid cash balance of €232 M on 30 June 2014, liquid assets position of €240 M Group revenues €63 M, including €18 M revenues from discontinued service operations Operating loss of continuing operations €15 M, ... [Published Virtual Strategy Magazine - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Charles River Laboratories International's (CRL) CEO James Foster on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. Welcome to the Charles River Laboratories Second Quarter 2014 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over ... [Published Seeking Alpha - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Charles River Beats on Q2 Earnings & Revenues, Outlook U…

Charles River Laboratories ( CRL - Snapshot Report ) reported second quarter 2014 earnings (excluding special items) of 97 cents per share, easily beating the Zacks Consensus Estimate of 82 cents and up from 73 cents in the year-ago quarter.Charles ... [Published Zacks.com - Aug 07 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 4 reports

Charles River acquires Galapagos' CRO services division

Charles River Laboratories International (CRL) has completed the previously announced acquisition of the CRO services division of Galapagos (GLPGF), which includes both Argenta and BioFocus. ... [Published PBR - News - Apr 01 2014]

Quotes

...55 million, compared to $584.17 million for the same period ended June 29, 2013. James Foster, chairman, president and CEO, said, "We are very pleased with the second-quarter performance, which is one of the strongest we have ever reported. Double-digit sales growth for the EMD, Biologics, and safety assessment businesses, and the acquisition of Argenta and BioFocus, drove mid-teens revenue growth in the quarter. Leverage from higher sales and our efficiency initiatives combined to generate a 33% increase in non-GAAP earnings per share. As a result, we are increasing our 2014 non-GAAP earnings guidance to a range of $3.25 to $3.35."
...We continue to execute on our novel targets, filling our pipeline with new opportunities," said Galapagos CEO Onno van de Stolpe. "Galapagos aims to deliver the 12 week data from DARWIN 1 with GLPG0634 in March 2015, starting a steady flow of Phase 2 readouts expected for GLPG0634 in rheumatoid arthritis and Crohn's next year and potentially triggering payments of $250 million from AbbVie. Galapagos is nearing some key valuation inflection points as it finishes up recruiting for these studies, with a healthy balance sheet to support further growth of our pipeline."
"We are continuing our focus on targeted sales efforts, which have been particularly successful with the mid-tier clients. And now that we have broadened our early-stage portfolio with the addition of early discovery capabilities, we are engaging in expanded discussions with existing clients and reaching potential clients who are interested in outsourcing entire drug discovery and development programs to a single provider. We believe these discussions will result in expanded and new strategic relationships across our global, mid-tier, and academic clients" Mr. Foster concluded...
Spokeswoman Elisabeth Goodwin told Outsourcing-pharma.com that Biofocus and Argenta contribute " in vitro drug discovery capabilities to CRL’s in vivo discovery capabilities."

More Content

All (20) | News (13) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
KISS supports Health Enterprise East Innovation... [Published Cambridge Network - Sep 02 2014]
KISS Continues to Ramp Up Investment in Young T... [Published WKRG - Aug 29 2014]
Hyderabad to become the Capital of Biosimilars:... [Published APN News - Aug 26 2014]
Charles River reports higher Q2 net income, upd... [Published Individual.com - Aug 21 2014]
Galapagos cash position of €232 M provides soli... [Published Noodls - Aug 18 2014]
CHARLES RIVER LABORATORIES : Announces Second-Q... [Published 4 Traders - Aug 14 2014]
KISS team cycles from London to Cambridge, rais... [Published Cambridge Network - Aug 14 2014]
CRL to buy Argenta and Biofocus from Galapagos ... [Published Outsourcing Pharma - Aug 11 2014]
Charles River's checkbook fuels a leap in revenue [Published Fierce CRO - Aug 11 2014]
Galapagos cash position of EU232 M provides sol... [Published Virtual Strategy Magazine - Aug 08 2014]
Charles River Laboratories International's (CRL... [Published Seeking Alpha - Aug 07 2014]
Charles River Beats on Q2 Earnings & Revenues, ... [Published Zacks.com - Aug 07 2014]
Charles River acquires Galapagos' CRO services ... [Published PBR - News - Apr 01 2014]
Charles River Laboratories Completes the Acquis... [Published EON Science - Apr 01 2014]
Charles River Laboratories Completes the Acquis... [Published Business Wire Science: Science News - Apr 01 2014]
Charles River Laboratories Completes the Acquis... [Published Business Wire Health News - Apr 01 2014]
Charles River Laboratories to Acquire the CRO S... [Published EON Science - Mar 13 2014]
Charles River Laboratories to Acquire the CRO S... [Published Business Wire Science: Science News - Mar 13 2014]
Charles River Laboratories to Acquire the CRO S... [Published Business Wire Health News - Mar 13 2014]
Van Herk Investments notify of 5.3% shareholdin... [Published GlobeNewswire - Jan 06 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Charles River acquires Galapagos' CRO services ... [Published PBR - News - Apr 01 2014]
Charles River Laboratories International (CRL) has completed the previously announced acquisition of the CRO services division of Galapagos (GLPGF), which includes both Argenta and BioFocus. ...
Charles River Laboratories Completes the Acquis... [Published EON Science - Apr 01 2014]
WILMINGTON, Mass.--(EON: Enhanced Online News)--Charles River completes the acquisition of Argenta and BioFocus from Galapagos NV ...
Charles River Laboratories Completes the Acquis... [Published Business Wire Science: Science News - Apr 01 2014]
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River completes the acquisition of Argenta and BioFocus from Galapagos NV ...
Charles River Laboratories Completes the Acquis... [Published Business Wire Health News - Apr 01 2014]
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River completes the acquisition of Argenta and BioFocus from Galapagos NV ...
Charles River Laboratories to Acquire the CRO S... [Published EON Science - Mar 13 2014]
WILMINGTON, Mass.--(EON: Enhanced Online News)--Charles River Laboratories has entered into a definitive agreement to acquire the CRO services division of Galapagos NV, which includes both Argenta and BioFocus, for approximately $179 million ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.